PRESS RELEASES

Corporate, financial, product, speech & presentation, press release - You name it!

HalioDx Signs an Agreement with SOHIN to Make Immunoscore® Colon Assay Available in Mexico

HalioDx SAS, an immuno-oncology diagnostic company, today announced that it has signed a distribution agreement with SOHIN (Mexico). Under the agreement, SOHIN becomes exclusive distributor of Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer in Mexico.

Oncologists and patients in Mexico will have access to Immunoscore® Colon, an assay which combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. The assay guides oncologists to decide on critical therapeutic options in stage II and stage III colon cancers[1]. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.

There are 6 000 new cases of Colon Cancer per year in Mexicotypo3/#_ftn2[2]which represent a relevant health priority in the country. For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore® Colon, relapse risk assessment will be improved for these patients,says Vincent Fert CEO of HalioDx. He added “We are delighted to have signed this agreement with SOHIN who has a proven record of success in the highly competitive cancer diagnostics market.”

Juana Ramirez, CEO of SOHIN, comments: "Our agreement with HalioDx will generate significant value for our customers. We were impressed with the Immunoscore® approach and HalioDx commitment to patient benefit with such innovation which, we believe, make a significant impact on colorectal cancer”.

Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study[3] conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147[4] study.


[1] Hermitte J Immunother Cancer 2016

[2] Source: World Health Organization – Cancer Country Profiles, 2014

[3] Pagès et al. The Lancet 2018

[4] Sinicrope et al. Poster presentation ASCO GI 2018